News
AGEN
4.970
-7.96%
-0.430
Weekly Report: what happened at AGEN last week (0408-0412)?
Weekly Report · 4d ago
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
Agenus Inc (NASDAQ:AGEN) released updated results from its Phase 1 clinical trial of a cancer therapy. The company also announced a one-for-twenty reverse stock split on Friday. William Blair sees potential in Agenus’s next-generation CTLA-4 antibody, botensilimab.
Benzinga · 04/12 18:18
BUZZ-U.S. STOCKS ON THE MOVE-Exxon, Oil stocks, Nextplat
The blue-chip Dow and the S&P 500 were on track for weekly losses on Friday. Most megacap growth stocks and chipmakers retreated, while some big banks fell after reporting dour quarterly earnings. The Dow Jones Industrial Average was down 0.84% at 38,136.43 and the Nasdaq Composite was down 1.08%.
Reuters · 04/12 16:23
Commit To Purchase Agenus At $1, Earn 2607.1% Annualized Using Options
NASDAQ · 04/12 15:38
Agenus reports updated Phase 1 data on colorectal cancer therapy
Agenus reports updated data from a Phase 1 study for its colorectal cancer therapy BOT/BAL. The biotech company plans to discuss “encouraging” interim Phase 2 data with the FDA. Agenus says it has finished enrollment for a Phase 2 study of the therapy.
Seeking Alpha · 04/12 13:11
Agenus Updates Phase 1 Data Of BOT/BAL Therapy In MSS Metastatic Colorectal Cancer
NASDAQ · 04/12 12:18
Agenus Announces Updated Phase 1 Data and Progress On BOT/BAL Development In Metastatic MSS Colorectal Cancer, Updated Phase 1 Data Demonstrate 12-Month Overall Survival (OS) Of 71% And 18-Month OS Of 62%
Benzinga · 04/12 11:32
AGENUS INC - COMPANY PLANS TO SUBMIT PHASE 2 DATA TO A MAJOR MEDICAL CONFERENCE IN SECOND HALF OF 2024
Reuters · 04/12 11:30
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
Agenus Inc. Announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC. The company is a leader in discovering and developing novel immunological agents to treat various cancers. In the Phase 1 trial of 77 patients with refractory MSS-CRC, a 23% overall response rate was observed.
Barchart · 04/12 06:30
Gold Moves Higher; Auddia Shares Surge
U.S. Stocks traded higher toward the end of trading on Monday. The Dow traded up 0.04% to 38,919.32 while the Nasdaq Composite gained 0.1%. Consumer discretionary shares jumped by 0.9% on Monday; health care shares fell 0.3%. Perion Network Ltd. Shares dropped 40% after the company slashed its FY24 revenue guidance. European shares closed mostly higher in Asia Pacific markets.
Benzinga · 04/08 18:51
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday's session. Auddia Inc. Shares jumped 231.7% to $4.72. The company announced a 1-for-20 reverse stock split of common stock.
Benzinga · 04/08 17:10
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Etao International Co (NASDAQ:ETAO) stock moved upwards by 96.6% to $4.9 during Monday's regular session. Adlai Nortye stock rose 47.3% and Longeveron shares rose 48.63% during the session. Losers include Universe Pharmaceuticals, Agenus and Vincerx Pharma.
Benzinga · 04/08 16:31
Crude Oil Moves Lower; Perion Network Shares Tumble
U.S. Stocks traded higher midway through trading on Monday. The Dow traded up 0.21% and the Nasdaq Composite gained over 50 points. Consumer discretionary shares jumped by 1% while energy shares fell by 0.6%. Perion Network Ltd. Slashed its FY24 revenue guidance and issued first-quarter outlook below estimates.
Benzinga · 04/08 16:12
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Public offering, a BTC rally, earnings reports and more are the biggest pre-market stock movers on Monday morning. Longeveron stock is rocketing 74% alongside a proposed public offering. U Power shares are soaring over 50% after announcing a commercial launch for an electric vehicle.
Investorplace · 04/08 11:26
Weekly Report: what happened at AGEN last week (0401-0405)?
Weekly Report · 04/08 11:14
RADCOM, Lotus Technology And 3 Stocks To Watch Heading Into Monday
Accenture plc agreed to acquire CLIMB to expand technology capabilities. Agenus Inc. Disclosed a 1-for-20 reverse stock split of common stock. Bragg Gaming Group Inc. Reported the resignation of its Chief Financial Officer Ronen Kannor.
Benzinga · 04/08 07:19
Agenus Announces A 1-For-20 Reverse Stock Split Of Common Stock, Which Will Go Into Effect On April 12, 2024
Agenus Inc. Is a leader in discovering and developing novel immunological agents to treat various cancers. The reverse stock split will go into effect on April 12, 2024. The par value of the Agenus' common stock will remain unchanged at $0.01 per share.
Benzinga · 04/05 20:33
AGENUS INC - EXPECTS THAT UPON OPENING OF TRADING ON APRIL 12, 2024, ITS COMMON STOCK WILL TRADE ON NASDAQ CAPITAL MARKET ON A SPLIT-ADJUSTED BASIS
Reuters · 04/05 20:30
*Agenus: Stockholders Have Approved 1-for-20 Reverse Split >AGEN
Dow Jones · 04/05 20:30
More
Webull provides a variety of real-time AGEN stock news. You can receive the latest news about Agenus through multiple platforms. This information may help you make smarter investment decisions.
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.